Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.76 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | KDM6B | O15054 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.43 |
| ▸ | ASPH | Q12797 | 3/20 | 0.42 |
| ▸ | KDM8 | Q8N371 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15528862 | 0.87 | KDM5B (1.00) | KDM5BKMT2AKDM4EKDM4CAURKA | |
| SCHEMBL1715643 | 0.80 | DHODH (0.63) | KDM5BP4HTMKMT2ACYP1A2CYP2C19 | |
| SCHEMBL6104425 | 0.78 | CISD1 (0.49) | KDM5BP4HTMPPARASTING1KMT2A | |
| SCHEMBL22609297 | 0.77 | P4HTM (0.48) | KDM5BP4HTMPPARASTING1KMT2A | |
| SCHEMBL18049776 | 0.75 | PDPK1 (0.49) | KDM5BP4HTMKMT2AMAPTKDM4E | |
| SCHEMBL15738084 | 0.75 | KDM5B (0.42) | KDM5BP4HTMKMT2ACYP1A2CYP2C19 | |
| SCHEMBL29582097 | 0.74 | KDM4C (0.76) | KDM5BKDM4EKDM4CKDM6BKDM4A | |
| SCHEMBL15818320 | 0.74 | KDM4C (0.76) | KDM5BKDM4EKDM4CKDM6BKDM4A | |
| SCHEMBL870110 | 0.74 | P4HTM (0.55) | P4HTMPPARASTING1KMT2ACYP1A2 | |
| SCHEMBL3146401 | 0.74 | KDM5B (0.62) | KDM5BKMT2AKDM4EKDM4CAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101868-B2 | Substituted arylamine derivatives and methods of use | AMGEN INC. (US) | 2006-09-05 | — | — | US | claimed |
| EP-1583744-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2005-10-12 | — | — | EP | claimed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | claimed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | claimed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | claimed |
| US-7101868-B2 | Substituted arylamine derivatives and methods of use | AMGEN INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1583744-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2005-07-14 | — | — | US | disclosed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | KDM5B 459/4885P4HTM 114/4885PPARA 487/4885 |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | KDM5B 459/4885P4HTM 114/4885PPARA 487/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | KDM5B 459/4885P4HTM 114/4885PPARA 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.